Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 65, Issue 8, 2005, Pages 739-745

  Yilmaz, F M ^a   Yilmaz, G ^a   Duranay, M ^b   Parpucu, H ^b   Senes M ^a   Tekeli, N ^b   Yucel D ^a,c  

^a MINISTRY OF HEALTH   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

^c SBAnkara Egitim ve Arastirma Hast   (Turkey)

Author keywords

Apolipoprotein A l and B; Apolipoprotein(a); Cardiac risk; Hemodialysis; Homocysteine; hs CRP; Peritoneal dialysis

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COULTER COUNTER; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGING; APOLIPOPROTEINS A; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LIPOPROTEIN(A); MALE; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 28744457968     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510500375271     Document Type: Article

References (26)

1. Cases A, Vera M, Lopez GJM. Cardiovascular risk in patients with chronic renal failure. Nefrologia 2002;22:68-74.
2. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
3. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.
4. Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-80.
5. Bostom AG, Lathrop L. Hyperhomocysteinemia in end stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 1997;52:10-20.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:112-119.
7. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-89.
8. Van Guldener C, Stam F, Stehower CD. Homocysteine metabolism in renal failure. Kidney Int 2001;78:234-7.
9. Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben Abdallah T, Massy ZA, Ben Mais Z, Lacour B, Mebazaa A. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. Clin Chem Lab Med 2003;41:675-80.
10. Eikelboom JW, Hankey GJ. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 2001;15:81-91.
11. Klusmann A, Ivens K, Schadewaldt P, Grabensee B, Heering P. Is homocysteine a risk factor for coronary heart disease in patients with terminal renal failure? Med Klin 2000;95:189-94.
12. Suliman ME. Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 2003;41:89-95.
13. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996;50:11-7.
14. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
15. Panichi V, Migliori M, De Pietro S. Plasma C-reactive protein in haemodilysis patients. Blood Purif 1999;17:142-8.
16. Uterman G. The mysteries of lipoprotein (a). Science 1989;246:904-16.
17. Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 1999;71:242-4.
18. Howard GC, Pizzo SV. Lipoprotein (a) and its role in atherothrombotic disease. Lab Invest 1993;69:373-86.
19. Sandkamp M, Funke H, Schulte H, Kohler E, Assmann G. Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-3.
20. Grainger DJ, Kirshenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-56.
21. Fytili CI, Passadakis PS, Progia EG, Kambouromiti GL, Panapoulou MI, Sambolos KI, et al. Is arterial hypertension an underlying factor in the increased serum Lp (a) levels in ESRD dialyzed patients? Ren Fail 2002;24:631-8.
22. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein in renal diseases. Am J Kidney Dis 1996;27:1-25.
23. Kimak E, Solski J. Serum lipoprotein(a) concentrations and apolipoprptein (a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Ren Fail 2002;24:187-95.
24. Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML. Apolipoprotein a phenotype and lipoprotein a level predict peritoneal dialysis patient mortality. Perit Dial Int 2002;22:492-9.
25. Kimak E, Solski J, Janicka L, Ksaziek A, Janicki K. Concentration Lp (a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Clin Chem Lab Med 2000;38:421-5.
26. Lowrie GR, Huang WH, Lew NL. Death risk predictors among peritoneal dialysis and hemodialysis patients: A preliminary comparison. Am J Kidney Dis 1995;26:220-8.